[go: up one dir, main page]

DE60136212D1 - Diagnose und behandlung von tumor-suppressor assoziierten krankheiten - Google Patents

Diagnose und behandlung von tumor-suppressor assoziierten krankheiten

Info

Publication number
DE60136212D1
DE60136212D1 DE60136212T DE60136212T DE60136212D1 DE 60136212 D1 DE60136212 D1 DE 60136212D1 DE 60136212 T DE60136212 T DE 60136212T DE 60136212 T DE60136212 T DE 60136212T DE 60136212 D1 DE60136212 D1 DE 60136212D1
Authority
DE
Germany
Prior art keywords
tslc1
expression
disorder
proliferating
reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136212T
Other languages
English (en)
Inventor
Roger Harper Reeves
Yoshinori Murakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
Johns Hopkins University
Original Assignee
National Cancer Center Japan
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan, Johns Hopkins University filed Critical National Cancer Center Japan
Application granted granted Critical
Publication of DE60136212D1 publication Critical patent/DE60136212D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DE60136212T 2000-08-15 2001-08-15 Diagnose und behandlung von tumor-suppressor assoziierten krankheiten Expired - Lifetime DE60136212D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22526400P 2000-08-15 2000-08-15
PCT/US2001/025690 WO2002014557A1 (en) 2000-08-15 2001-08-15 Diagnosis and treatment of tumor-suppressor associated disorders

Publications (1)

Publication Number Publication Date
DE60136212D1 true DE60136212D1 (de) 2008-11-27

Family

ID=22844210

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136212T Expired - Lifetime DE60136212D1 (de) 2000-08-15 2001-08-15 Diagnose und behandlung von tumor-suppressor assoziierten krankheiten

Country Status (7)

Country Link
US (3) US6596493B1 (de)
EP (1) EP1339871B1 (de)
AT (1) ATE411037T1 (de)
AU (1) AU2001286514A1 (de)
CA (1) CA2419529C (de)
DE (1) DE60136212D1 (de)
WO (1) WO2002014557A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596493B1 (en) * 2000-08-15 2003-07-22 The Johns Hopkins University School Of Medicine Diagnosis and treatment of tumor-suppressor associated disorders
ES2298467T3 (es) * 2003-03-31 2008-05-16 Stichting Researchfonds Pathologie Deteccion de canceres invasivos inducidos por hpv y sus lesiones precursoras con potencial invasivo.
EP1648935A2 (de) * 2003-07-25 2006-04-26 Amgen Inc. Antagonisten und agonisten von ldcam und anwendungsverfahren
AU2006216291B2 (en) * 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
WO2008026010A1 (en) * 2006-08-29 2008-03-06 Oxford Genome Sciences (Uk) Ltd Identification of protein associated with hepatocellular carcinoma, glioblastoma and lung cancer
CN101153336B (zh) 2006-09-27 2011-09-07 香港中文大学 检测dna甲基化程度的方法和试剂盒
US9102948B2 (en) 2006-11-17 2015-08-11 22Nd Century Limited, Llc Regulating alkaloids
GB2455634A (en) * 2007-12-20 2009-06-24 Ucb Pharma Sa Treatment of cancer
US20110159499A1 (en) * 2009-11-25 2011-06-30 Quantalife, Inc. Methods and compositions for detecting genetic material
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
EP3483285B1 (de) 2011-02-09 2021-07-14 Bio-Rad Laboratories, Inc. Analyse von nukleinsäuren
WO2013163428A1 (en) * 2012-04-25 2013-10-31 The Regents Of The University Of Colorado Detection of ret fusions in cancer
JP7190165B2 (ja) * 2018-04-13 2022-12-15 学校法人近畿大学 慢性腎臓病罹患の可能性の判定のための方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552277A (en) 1994-07-19 1996-09-03 The Johns Hopkins University School Of Medicine Genetic diagnosis of prostate cancer
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
AU7829398A (en) 1997-06-09 1998-12-30 University Of Southern California A cancer diagnostic method based upon dna methylation differences
WO2000008158A2 (en) * 1998-08-07 2000-02-17 Immunex Corporation Molecules designated ldcam
EP1124850A4 (de) * 1998-10-28 2005-10-19 Human Genome Sciences Inc 12 menschliche sekretierte proteine
AU1618500A (en) * 1998-11-12 2000-05-29 Incyte Pharmaceuticals, Inc. Human cell surface receptor proteins
US6596493B1 (en) * 2000-08-15 2003-07-22 The Johns Hopkins University School Of Medicine Diagnosis and treatment of tumor-suppressor associated disorders

Also Published As

Publication number Publication date
EP1339871B1 (de) 2008-10-15
WO2002014557A1 (en) 2002-02-21
EP1339871A1 (de) 2003-09-03
US20030165974A1 (en) 2003-09-04
US7153657B2 (en) 2006-12-26
US20070072224A1 (en) 2007-03-29
US6596493B1 (en) 2003-07-22
CA2419529A1 (en) 2002-02-21
ATE411037T1 (de) 2008-10-15
US7833712B2 (en) 2010-11-16
CA2419529C (en) 2013-02-12
AU2001286514A1 (en) 2002-02-25
EP1339871A4 (de) 2005-08-17

Similar Documents

Publication Publication Date Title
Ribero et al. Effect of age on melanoma risk, prognosis and treatment response
DE60136212D1 (de) Diagnose und behandlung von tumor-suppressor assoziierten krankheiten
Wang et al. Pancreatic cancer-initiating cell exosome message transfer into noncancer-initiating cells: the importance of CD44v6 in reprogramming
Mckenzie et al. Role of the apoptotic and mitotic regulator survivin in melanoma
Su et al. CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
Clere et al. Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis
WO2007092414A3 (en) Use of phosphatases to treat tumors overexpressing n-cor
TW200639165A (en) Certain substituted ureas as modulators of kinase activity
JP2013525283A5 (de)
ATE175996T1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
Furukawa et al. PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation
Doma et al. Skin tumorigenesis stimulated by Raf inhibitors relies upon Raf functions that are dependent and independent of ERK
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
Zhuang et al. MicroRNA‐30e‐5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma
Kanthesh et al. Enhanced K+ secretion in dextran sulfate-induced colitis reflects upregulation of large conductance apical K+ channels (BK; Kcnma1)
IL151448A0 (en) Proteins
Kuo et al. Effects of Helicobacter pylori infection in gastrointestinal tract malignant diseases: From the oral cavity to rectum
Liu et al. ENKUR recruits FBXW7 to ubiquitinate and degrade MYH9 and further suppress MYH9‐induced deubiquitination of β‐catenin to block gastric cancer metastasis
Zhang et al. N-myc downstream-regulated gene 1 promotes apoptosis in colorectal cancer via up-regulating death receptor 4
Prasad et al. The thioredoxin system determines CHK1 inhibitor sensitivity via redox-mediated regulation of ribonucleotide reductase activity
Flitney et al. Antitumor actions of ruthenium (III)-based nitric oxide scavengers and nitric oxide synthase inhibitors
Ades et al. Targeting the cellular signaling: BRAF inhibition and beyond for the treatment of metastatic malignant melanoma
Pak et al. Clonorchis sinensis excretory–secretory products regulate migration and invasion in cholangiocarcinoma cells via extracellular signal-regulated kinase 1/2/nuclear factor-κB-dependent matrix metalloproteinase-9 expression
AU2002367317A8 (en) Psoriasin expression by breast epithelial cells

Legal Events

Date Code Title Description
8364 No opposition during term of opposition